JCM
OTLK icon

Jacobi Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Jacobi Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-150
Closed -$7K – 1034
2021
Q3 		$7K Hold
150
– – ﹤0.01% 1133
2021
Q2 		$7K Hold
150
– – ﹤0.01% 1097
2021
Q1 		$7K Buy
+150
New +$5.74K ﹤0.01% 1058

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobi Capital Management's OTLK Position: Q4 2021 in Review

Jacobi Capital Management sold out of Outlook Therapeutics (OTLK) in Q4 2021, closing a stake of 150 shares — an estimated $7K sold.

Jacobi Capital Management first reported a position in OTLK in Q1 2021 and held it in 3 quarters. The position peaked at $7K in Q3 2021. 70 funds tracked by Wall St. Rank hold OTLK as of Q4 2021.

  • Jacobi Capital Management reported no remaining Outlook Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 150 Outlook Therapeutics shares in Q4 2021, an estimated $7K.
  • Jacobi Capital Management first reported a position in Outlook Therapeutics in Q1 2021 and held it in 3 quarters.
  • Jacobi Capital Management's Outlook Therapeutics position peaked at $7K in Q3 2021.
  • 70 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.